Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Intrauterine growth restriction leads to a dysregulation of Wilms' tumour supressor gene 1 (WT1) and to early podocyte alterations.

Menendez-Castro C, Hilgers KF, Amann K, Daniel C, Cordasic N, Wachtveitl R, Fahlbusch F, Plank C, Dötsch J, Rascher W, Hartner A.

Nephrol Dial Transplant. 2013 Jun;28(6):1407-17. doi: 10.1093/ndt/gfs517. Epub 2012 Dec 9.

2.

TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.

Sakairi T, Abe Y, Kopp JB.

Nephrol Dial Transplant. 2011 Sep;26(9):2746-52. doi: 10.1093/ndt/gfr061. Epub 2011 Mar 4.

3.

Murine Denys-Drash syndrome: evidence of podocyte de-differentiation and systemic mediation of glomerulosclerosis.

Patek CE, Fleming S, Miles CG, Bellamy CO, Ladomery M, Spraggon L, Mullins J, Hastie ND, Hooper ML.

Hum Mol Genet. 2003 Sep 15;12(18):2379-94. Epub 2003 Jul 22.

4.

Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms' tumor-1 protein used as a podocyte marker.

Su J, Li SJ, Chen ZH, Zeng CH, Zhou H, Li LS, Liu ZH.

Diabetes Res Clin Pract. 2010 Feb;87(2):167-75. doi: 10.1016/j.diabres.2009.10.022. Epub 2009 Dec 6.

PMID:
19969384
5.

Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.

Zhou G, Cheung AK, Liu X, Huang Y.

Clin Sci (Lond). 2014 May;126(10):707-20. doi: 10.1042/CS20130223.

PMID:
24195695
6.

The nephron number counts--from womb to tomb.

Rookmaaker MB, Joles JA.

Nephrol Dial Transplant. 2013 Jun;28(6):1325-8. doi: 10.1093/ndt/gfs538. Epub 2012 Dec 11. No abstract available.

7.

Intra-renal and urinary mRNA expression of podocyte-associated molecules for the estimation of glomerular podocyte loss.

Wang G, Lai FM, Lai KB, Chow KM, Kwan BC, Li KT, Szeto CC.

Ren Fail. 2010 Jan;32(3):372-9. doi: 10.3109/08860221003611737.

PMID:
20370455
8.

Detection of expressional changes induced by intrauterine growth restriction in the developing rat mammary gland via exploratory pathways analysis.

Beinder L, Faehrmann N, Wachtveitl R, Winterfeld I, Hartner A, Menendez-Castro C, Rauh M, Ruebner M, Huebner H, Noegel SC, Doerr HG, Rascher W, Fahlbusch FB.

PLoS One. 2014 Jun 23;9(6):e100504. doi: 10.1371/journal.pone.0100504. eCollection 2014.

9.

The major podocyte protein nephrin is transcriptionally activated by the Wilms' tumor suppressor WT1.

Wagner N, Wagner KD, Xing Y, Scholz H, Schedl A.

J Am Soc Nephrol. 2004 Dec;15(12):3044-51.

10.

Close relations between podocyte injuries and membranous proliferative glomerulonephritis in autoimmune murine models.

Kimura J, Ichii O, Otsuka S, Sasaki H, Hashimoto Y, Kon Y.

Am J Nephrol. 2013;38(1):27-38. doi: 10.1159/000353093. Epub 2013 Jun 26.

PMID:
23817053
11.

Genetic low nephron number hypertension is associated with dysregulation of the hepatic and renal insulin-like growth factor system during nephrogenesis.

Rothermund L, Nierhaus M, Fialkowski O, Freese F, Ibscher R, Mieschel S, Kossmehl P, Grimm D, Wehland M, Kreutz R.

J Hypertens. 2006 Sep;24(9):1857-64.

PMID:
16915036
12.

Tolvaptan, a selective oral vasopressin V2 receptor antagonist, ameliorates podocyte injury in puromycin aminonucleoside nephrotic rats.

Okada T, Sakaguchi T, Hatamura I, Saji F, Negi S, Otani H, Muragaki Y, Kawachi H, Shigematsu T.

Clin Exp Nephrol. 2009 Oct;13(5):438-46. doi: 10.1007/s10157-009-0196-0. Epub 2009 May 19.

PMID:
19452240
13.

Uteroplacental insufficiency affects kidney VEGF expression in a model of IUGR with compensatory glomerular hypertrophy and hypertension.

Baserga M, Bares AL, Hale MA, Callaway CW, McKnight RA, Lane PH, Lane RH.

Early Hum Dev. 2009 Jun;85(6):361-7. doi: 10.1016/j.earlhumdev.2008.12.015. Epub 2009 Feb 1.

14.

De novo expression of podocyte proteins in parietal epithelial cells in experimental aging nephropathy.

Zhang J, Hansen KM, Pippin JW, Chang AM, Taniguchi Y, Krofft RD, Pickering SG, Liu ZH, Abrass CK, Shankland SJ.

Am J Physiol Renal Physiol. 2012 Mar 1;302(5):F571-80. doi: 10.1152/ajprenal.00516.2011. Epub 2011 Nov 30.

15.

Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury.

Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, Longaretti L, Conti S, Kawachi H, Hill P, Remuzzi G, Remuzzi A.

Am J Pathol. 2006 Jan;168(1):42-54.

16.

Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.

Zhang M, Liu M, Xiong M, Gong J, Tan X.

J Ethnopharmacol. 2012 May 7;141(1):111-8. doi: 10.1016/j.jep.2012.02.007. Epub 2012 Feb 14.

PMID:
22353431
17.

Early and late postnatal myocardial and vascular changes in a protein restriction rat model of intrauterine growth restriction.

Menendez-Castro C, Fahlbusch F, Cordasic N, Amann K, Münzel K, Plank C, Wachtveitl R, Rascher W, Hilgers KF, Hartner A.

PLoS One. 2011;6(5):e20369. doi: 10.1371/journal.pone.0020369. Epub 2011 May 31.

18.

Influence of bushenhuoxue on podocytes of focal segmental glomerulosclerosis mice.

Zuo C, Tan X, Jia S, Zhang M, Zhang D.

J Tradit Chin Med. 2014 Oct;34(5):591-6.

PMID:
25417411
19.

Hsf-1 affects podocyte markers NPHS1, NPHS2 and WT1 in a transgenic mouse model of TTRVal30Met-related amyloidosis.

Petrakis I, Mavroeidi V, Stylianou K, Andronikidi E, Lioudaki E, Perakis K, Stratigis S, Vardaki E, Zafeiri M, Giannakakis K, Plaitakis A, Amoiridis G, Saraiva MJ, Daphnis E.

Amyloid. 2013 Sep;20(3):164-72. doi: 10.3109/13506129.2013.814046. Epub 2013 Jul 5.

PMID:
23829269
20.

Variable expression of podocyte-related markers in the glomeruloid bodies in Wilms tumor.

Kanemoto K, Takahashi S, Shu Y, Usui J, Tomari S, Yan K, Hamazaki Y, Nagata M.

Pathol Int. 2003 Sep;53(9):596-601.

PMID:
14507316
Items per page

Supplemental Content

Write to the Help Desk